A recent aggregate study, published by Frontiers in Neuroscience and conducted by Ezio Carboni, Anna Carta, Elena Carboni, and Antonello Novelli, emphasizes the significant promise of ketamine as a treatment option for chronic and treatment-resistant depression. Ketamine, originally developed as an anesthetic and analgesic drug in the 1970s, has established itself as a safe alternative in medical settings, including hospitals, clinics, and battlefields. Its unique characteristic of not depressing the respiratory or circulatory systems has positioned it as a preferred choice for surgical procedures globally.
Over the years, ketamine has gained recognition for its potential in treating depression, especially for individuals who do not respond to traditional therapies. The study’s findings highlight the effectiveness of ketamine in providing relief to those suffering from chronic and treatment-resistant depression. As a dissociative anesthetic, ketamine acts on various neurotransmitters in the brain, including glutamate, AMPA, BDNF, eEF2, and glycogen synthase kinase 3. These interactions contribute to its rapid antidepressant effects and the modulation of neural activity associated with depressive symptoms.
The research conducted by Carboni and colleagues sheds light on the unique properties of ketamine that set it apart from other medications. Its ability to produce immediate results, as opposed to the delayed onset of traditional antidepressants, offers a promising alternative for patients seeking relief. Additionally, studies have shown the lasting anti-depressive benefits of ketamine and its derivatives, such as esketamine (Spravato) and R-ketamine, which demonstrate efficacy in treating treatment-resistant depression.
As ketamine gains momentum as a potential breakthrough treatment for depression, it is crucial to dispel misconceptions and promote awareness about its proper medical use. The extensive history of ketamine’s safe administration in various medical settings supports its credibility as a viable option for depression treatment. By furthering research and understanding, we can enhance the conversation surrounding mental health and provide individuals with more effective treatment options to improve their well-being.
Despite ketamine’s long and successful use as an anesthetic, it has only recently, within the last decade, started to gain notoriety as a breakthrough treatment for depression and substance abuse disorders. This recognition of ketamine’s potential for treating depression comes from its rapid onset and relatively low risk of severe side effects. Unlike traditional SSRIs that take several weeks or longer to begin working, ketamine has been shown to have a near-immediate impact on patients who receive the drug.
As reported by Carboni, ketamine and its derivative drug esketamine affect brain NMDA (glutamate) transmission. This impact on the available levels of glutamate is believed to be responsible for ketamine rapid antidepressant effects. However, research into this and other areas of depression treatment is hampered by a lack of available animal studies.
Carboni proposes that ketamine also significantly impacts other neural transmitters, such AMPA, BDNF, eEF2, and glycogen synthase kinase 3. All of which are thought to be partially responsible for depressive symptoms in patients. Furthermore, Carboni Et. Al. postulates that ketamine stimulating qualities also positively affect patients with depressive symptoms, particularly those with treatment-resistant depression.
This may be due to ketamine’s ability to alter background synaptic activity, changing how some synaptic pathways in the mind that have become locked into depression-related states transmit information. This rewiring of neural activity is thought to allow data to be processed in new ways, potentially relieving depressive symptoms.
Carboni shows that ketamine’s ability to break free locked in synapses was first noted in research conducted by Berman et al. in the early 2000s. Berman’s research showed that patients with depressive symptoms given ketamine showed significant improvement in as little as 72 hours. Notably, this rapid relief from depressive symptoms was not experienced by the control group who received a placebo only.
Furthermore, trials conducted by Yang et al., 2019a and Canuso et al., 2018 showed both esketamine (Spravato) and R-ketamine provide rapid relief to patients with treatment-resistant depression. Interestingly R-ketamine, while being less potent than esketamine, showed longer-lasting anti-depressive benefits and required less follow-up course of the drug to maintain its anti-depressive effects.
While research into ketamine and its derivatives is still relatively new, research and trials like those mentioned above show that the drug has strong therapeutic potential. Particularly for those with major mood disorders or treatment-resistant depression. One of the most critical aspects of research like that detailed in this article is its ability to inform the general public about these new tools in the fight against mental illness.
Unfortunately, the public has long viewed ketamine as a party drug, leading to widespread misinformation and stigma around its use. As knowledge about the benefits of drugs like ketamine and even other psychedelics grows, it will be critical that the people stay engaged and become part of the greater conversation around not just ketamine but mental health as a whole.
David Connell is a U.S. Air Force Veteran writer and author of Cooking with Magic: The Psilocybin Cookbook. David holds a B.A. in Communications and Creative Writing from the University of Tennessee, Knoxville. Connect with him about drug policy reform, his thoughts on research in novel psychedelic therapies, creative writing, and his unabashed love for Science Fiction on Twitter, LinkedIn, and Instagram.
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., et al. (2018). Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am. J. Psychiatry 175, 620–630. doi: 10.1176/appi.ajp.2018.17060720
Carboni, E., Carta, A. R., Carboni, E., & Novelli, A. (1AD, January 1). Repurposing ketamine in depression and related disorders: Can this enigmatic drug achieve success? Frontiers. Retrieved December 16, 2021, from https://www.frontiersin.org/articles/10.3389/fnins.2021.657714/full
Yang, C., Wardenaar, K. J., Bosker, F. J., Li, J., and Schoevers, R. A. (2019a). Inflammatory markers and treatment outcome in treatment-resistant depression: a systematic review. J. Affect. Disord. 257, 640–649. doi: 10.1016/j.jad.2019.07.045
The post Aggregate Study on the Efficacy of Ketamine to Treat Depression Shows Promising Results. appeared first on ketamine.news.